Browsing Tag
NHS
18 posts
AbbVie’s bold gamble: Can Elahere really launch in the UK at full U.S. list price?
AbbVie plans to launch ovarian cancer drug Elahere in UK at U.S. price—testing NICE, NHS, and investor confidence in oncology pricing norms.
Can AI paperwork tools finally fix NHS discharge delays and free up hospital beds?
UK government’s AI Exemplars plan promises to cut NHS discharge delays and transform public services. Find out how these projects could scale.
Assura rejects KKR’s advances and backs Primary Health Properties’ £1.8bn takeover offer
Why Assura backed PHP’s £1.79B offer over KKR’s cash bid in a high-stakes UK healthcare real estate battle. Read the full breakdown now.
Can Trividia’s low-cost insulin pen needles improve diabetes care across the NHS?
Trividia Health UK launches TRUEplus 5-Bevel Pen Needles in the UK, aiming to improve diabetes injection comfort at a lower cost. Find out what this means.
Blood test for 10 cancers enters large-scale trial stage in UK, backed by Proteotype and NHS
ENLIGHTEN, a UK-developed blood test that detects up to 10 cancers early, reaches key trial milestone with 450+ participants; Proteotype Diagnostics leads effort.
How is the UK’s ‘Plan for Change’ strategy shaping its AI-driven economic growth goals?
Discover how the UK’s ‘Plan for Change’ uses AI to transform healthcare, policing, productivity, and growth across six national missions.
How AI is transforming cancer diagnosis and treatment planning in 2025
AI is reshaping cancer care—improving diagnosis, guiding treatment, and boosting efficiency across hospitals. Discover how it's redefining oncology workflows in 2025.
Primary Health Properties makes £1.7bn offer to acquire Assura Plc
Primary Health Properties tables £1.68B offer for Assura Plc, aiming to form a top UK healthcare REIT. Explore the deal’s terms, premiums, and strategic impact.
KKR and Stonepeak launch £1.6bn bid to take Assura private via scheme of arrangement
Find out how KKR and Stonepeak plan to reshape UK healthcare infrastructure through a £1.6B buyout of FTSE 250 REIT Assura plc.
Vertex Pharmaceuticals bags UK approval for ALYFTREK, a next-generation cystic fibrosis treatment
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation…